ES2793237T3 - Composiciones y métodos para el tratamiento de trastornos del SNC - Google Patents
Composiciones y métodos para el tratamiento de trastornos del SNC Download PDFInfo
- Publication number
- ES2793237T3 ES2793237T3 ES15862506T ES15862506T ES2793237T3 ES 2793237 T3 ES2793237 T3 ES 2793237T3 ES 15862506 T ES15862506 T ES 15862506T ES 15862506 T ES15862506 T ES 15862506T ES 2793237 T3 ES2793237 T3 ES 2793237T3
- Authority
- ES
- Spain
- Prior art keywords
- substituted
- sustituidoonosustitui
- unsubstituted
- alkyl
- alkynyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C*C(CC1)(*2)CCCCC12C([C@@](CC1)[C@@](C)(CC2)[C@@]1[C@](CC1)[C@]2[C@@](CC2)[C@@]1C[C@]2(*)O)=O Chemical compound C*C(CC1)(*2)CCCCC12C([C@@](CC1)[C@@](C)(CC2)[C@@]1[C@](CC1)[C@]2[C@@](CC2)[C@@]1C[C@]2(*)O)=O 0.000 description 3
- BXQBBQCXJPQWIX-JGANGFLVSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(N(C)OC)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(N(C)OC)=O BXQBBQCXJPQWIX-JGANGFLVSA-N 0.000 description 3
- NIFGSSOFWIKTTO-IXGGNEMYSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(c(cc1)ccc1OC)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(c(cc1)ccc1OC)=O NIFGSSOFWIKTTO-IXGGNEMYSA-N 0.000 description 2
- SEMSEQLEIVTYIT-XPUKREFJSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(c1c[n](C)nc1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(c1c[n](C)nc1)=O SEMSEQLEIVTYIT-XPUKREFJSA-N 0.000 description 2
- BQXJQPPZJAMDRO-IRTDTLKWSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(c1cccnc1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(c1cccnc1)=O BQXJQPPZJAMDRO-IRTDTLKWSA-N 0.000 description 2
- NYPYPOZNGOXYSU-UHFFFAOYSA-N Brc1cnccc1 Chemical compound Brc1cnccc1 NYPYPOZNGOXYSU-UHFFFAOYSA-N 0.000 description 1
- SONURDFYCRBLJJ-UHFFFAOYSA-N CC(C)(C)Cc(cc(cc1)OC(F)(F)F)c1Br Chemical compound CC(C)(C)Cc(cc(cc1)OC(F)(F)F)c1Br SONURDFYCRBLJJ-UHFFFAOYSA-N 0.000 description 1
- WYFBCWCQRFSRTR-UGFXULLGSA-N CC(CC1)(C(CC2)C(N(C)OC)O)[C@@H]2C(CC2)[C@H]1C(CC1)[C@H]2C[C@]1(C)O Chemical compound CC(CC1)(C(CC2)C(N(C)OC)O)[C@@H]2C(CC2)[C@H]1C(CC1)[C@H]2C[C@]1(C)O WYFBCWCQRFSRTR-UGFXULLGSA-N 0.000 description 1
- VFQHKWBPUQVIIX-HNLJAVFUSA-N CCc(cc1)ccc1C([C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@H](CC2)[C@@H]1C[C@]2(C)O)=O Chemical compound CCc(cc1)ccc1C([C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@H](CC2)[C@@H]1C[C@]2(C)O)=O VFQHKWBPUQVIIX-HNLJAVFUSA-N 0.000 description 1
- QJPJQTDYNZXKQF-UHFFFAOYSA-N COc(cc1)ccc1Br Chemical compound COc(cc1)ccc1Br QJPJQTDYNZXKQF-UHFFFAOYSA-N 0.000 description 1
- PLDWAJLZAAHOGG-UHFFFAOYSA-N COc1cc(Br)ccc1 Chemical compound COc1cc(Br)ccc1 PLDWAJLZAAHOGG-UHFFFAOYSA-N 0.000 description 1
- FMMGKUSODOYJNI-YZECAMMGSA-N C[C@@](CC1)([C@@H](CO)CC2)[C@@H]2[C@H](CC2)[C@H]1C(CC1)[C@H]2C[C@]1(C)O Chemical compound C[C@@](CC1)([C@@H](CO)CC2)[C@@H]2[C@H](CC2)[C@H]1C(CC1)[C@H]2C[C@]1(C)O FMMGKUSODOYJNI-YZECAMMGSA-N 0.000 description 1
- BXQBBQCXJPQWIX-OOBGCICNSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1C(C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(N(C)OC)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1C(C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(N(C)OC)=O BXQBBQCXJPQWIX-OOBGCICNSA-N 0.000 description 1
- BXQBBQCXJPQWIX-OXZJNGKUSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1C(C)(CC1)[C@H]3C[C@]1(C)O)[C@H]2C(N(C)OC)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1C(C)(CC1)[C@H]3C[C@]1(C)O)[C@H]2C(N(C)OC)=O BXQBBQCXJPQWIX-OXZJNGKUSA-N 0.000 description 1
- IMPAMQFUNACDKU-HVOJCETBSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(N(C)OC)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(N(C)OC)=O IMPAMQFUNACDKU-HVOJCETBSA-N 0.000 description 1
- DIWIVQFXGGCLPP-OPPIBPMMSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(c(cc1)ccc1Cl)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(c(cc1)ccc1Cl)=O DIWIVQFXGGCLPP-OPPIBPMMSA-N 0.000 description 1
- AFOVZRJRFJJSCN-BQTKJZEUSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(c(cccc1)c1-c1ccccc1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(c(cccc1)c1-c1ccccc1)=O AFOVZRJRFJJSCN-BQTKJZEUSA-N 0.000 description 1
- JKEOKYHKBODHTJ-XHDFEYEVSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(c1cc(OC)ccc1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(c1cc(OC)ccc1)=O JKEOKYHKBODHTJ-XHDFEYEVSA-N 0.000 description 1
- LAFOSFCDXQCVHB-PYTYXIMMSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(c1ccc2OCOc2c1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(c1ccc2OCOc2c1)=O LAFOSFCDXQCVHB-PYTYXIMMSA-N 0.000 description 1
- XECHMMJEUXWHGU-CVTCDJMJSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(c1cnccc1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(c1cnccc1)=O XECHMMJEUXWHGU-CVTCDJMJSA-N 0.000 description 1
- IIQSWUITXQZSOC-VITIKHFTSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(c1ncccc1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(c1ncccc1)=O IIQSWUITXQZSOC-VITIKHFTSA-N 0.000 description 1
- IMPAMQFUNACDKU-WMCSDWRFSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(C)O)[C@H]2C(N(C)OC)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(C)O)[C@H]2C(N(C)OC)=O IMPAMQFUNACDKU-WMCSDWRFSA-N 0.000 description 1
- JVSVRAZEEQMHRW-AXLRXMLQSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(C)O)[C@H]2C(c(cc1)cc(cc2)c1cc2OC)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(C)O)[C@H]2C(c(cc1)cc(cc2)c1cc2OC)=O JVSVRAZEEQMHRW-AXLRXMLQSA-N 0.000 description 1
- YJGOWFOYWPTEJL-AMHTVAQWSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(C)O)[C@H]2C(c(cccc1)c1F)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(C)O)[C@H]2C(c(cccc1)c1F)=O YJGOWFOYWPTEJL-AMHTVAQWSA-N 0.000 description 1
- FXIXTMXELBPGRT-QPSBLSKISA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(C)O)[C@H]2C(c1cc(C)cc(C)c1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(C)O)[C@H]2C(c1cc(C)cc(C)c1)=O FXIXTMXELBPGRT-QPSBLSKISA-N 0.000 description 1
- UPJNBIDNGVVMBQ-YTKMTPDTSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(C)O)[C@H]2C(c1cc(C)ccc1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(C)O)[C@H]2C(c1cc(C)ccc1)=O UPJNBIDNGVVMBQ-YTKMTPDTSA-N 0.000 description 1
- XECHMMJEUXWHGU-NYBDTYKHSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(C)O)[C@H]2C(c1cnccc1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(C)O)[C@H]2C(c1cnccc1)=O XECHMMJEUXWHGU-NYBDTYKHSA-N 0.000 description 1
- AQVOKSMAFDLHSZ-LSBZSBGNSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(c(cc1)ccc1F)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(c(cc1)ccc1F)=O AQVOKSMAFDLHSZ-LSBZSBGNSA-N 0.000 description 1
- UXTNTNONGLSRPS-BAEGCWTCSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(c(ccc1c2)cc1ccc2OC)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(c(ccc1c2)cc1ccc2OC)=O UXTNTNONGLSRPS-BAEGCWTCSA-N 0.000 description 1
- AOCQUGONQNKETE-YOOIHLMRSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(c(cccc1)c1-c1ccccc1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(c(cccc1)c1-c1ccccc1)=O AOCQUGONQNKETE-YOOIHLMRSA-N 0.000 description 1
- CDKGIZWTBDQYNQ-CFRBNIRDSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(c(cccc1)c1F)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(c(cccc1)c1F)=O CDKGIZWTBDQYNQ-CFRBNIRDSA-N 0.000 description 1
- WHVNIGQKCYYBTR-DVLJETOHSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(c(cccc1)c1OC)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(c(cccc1)c1OC)=O WHVNIGQKCYYBTR-DVLJETOHSA-N 0.000 description 1
- XMQWZNDCUVFXMF-RUJUVKCNSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(c1cc(C)cc(C)c1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(c1cc(C)cc(C)c1)=O XMQWZNDCUVFXMF-RUJUVKCNSA-N 0.000 description 1
- KFLFAZFTRODZCS-IXGGNEMYSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(c1cc(OC)ccc1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(c1cc(OC)ccc1)=O KFLFAZFTRODZCS-IXGGNEMYSA-N 0.000 description 1
- YCVRUDFRAJYOKO-QNMTVONFSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(c1ccc(C)cc1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(c1ccc(C)cc1)=O YCVRUDFRAJYOKO-QNMTVONFSA-N 0.000 description 1
- ISTXQAMLZMGNPQ-QCTCPQKBSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(c1n[n](C)cc1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(c1n[n](C)cc1)=O ISTXQAMLZMGNPQ-QCTCPQKBSA-N 0.000 description 1
- SEVLRZGBSQUYHK-DWQFDVHQSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@H]3C[C@]1(C)O)[C@H]2C(c(cc1)ccc1OC(F)(F)F)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@H]3C[C@]1(C)O)[C@H]2C(c(cc1)ccc1OC(F)(F)F)=O SEVLRZGBSQUYHK-DWQFDVHQSA-N 0.000 description 1
- WWZHJUNHNDBLRT-SCNDPVEVSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@H]3C[C@]1(C)O)[C@H]2C(c1c(C)cccc1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@H]3C[C@]1(C)O)[C@H]2C(c1c(C)cccc1)=O WWZHJUNHNDBLRT-SCNDPVEVSA-N 0.000 description 1
- SRGHJJJUTKJFKU-OXIOBPKQSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@H]3C[C@]1(C)O)[C@H]2C(c1cc(C)ccc1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@H]3C[C@]1(C)O)[C@H]2C(c1cc(C)ccc1)=O SRGHJJJUTKJFKU-OXIOBPKQSA-N 0.000 description 1
- YZOHCRGGSJMHLY-DWQFDVHQSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@H]3C[C@]1(C)O)[C@H]2C(c1cccc(Cl)c1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@H]3C[C@]1(C)O)[C@H]2C(c1cccc(Cl)c1)=O YZOHCRGGSJMHLY-DWQFDVHQSA-N 0.000 description 1
- PXUVAJPKTKRBER-WOIMZXFXSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](COC)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(c(cc1)ccc1Cl)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](COC)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(c(cc1)ccc1Cl)=O PXUVAJPKTKRBER-WOIMZXFXSA-N 0.000 description 1
- RVEPZQXTBSNCQS-NKJUZJLCSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](COC)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(c(cccc1)c1F)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](COC)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(c(cccc1)c1F)=O RVEPZQXTBSNCQS-NKJUZJLCSA-N 0.000 description 1
- IPWBFGUBXWMIPR-UHFFFAOYSA-N Fc1ccccc1Br Chemical compound Fc1ccccc1Br IPWBFGUBXWMIPR-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J33/002—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2014092369 | 2014-11-27 | ||
| PCT/CN2015/095765 WO2016082789A1 (en) | 2014-11-27 | 2015-11-27 | Compositions and methods for treating cns disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2793237T3 true ES2793237T3 (es) | 2020-11-13 |
Family
ID=56073637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15862506T Active ES2793237T3 (es) | 2014-11-27 | 2015-11-27 | Composiciones y métodos para el tratamiento de trastornos del SNC |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US10774108B2 (enExample) |
| EP (2) | EP3719029A1 (enExample) |
| JP (3) | JP6893173B2 (enExample) |
| CY (1) | CY1123200T1 (enExample) |
| DK (1) | DK3224269T3 (enExample) |
| ES (1) | ES2793237T3 (enExample) |
| HR (1) | HRP20200840T1 (enExample) |
| HU (1) | HUE049014T2 (enExample) |
| LT (1) | LT3224269T (enExample) |
| ME (1) | ME03749B (enExample) |
| PL (1) | PL3224269T3 (enExample) |
| PT (1) | PT3224269T (enExample) |
| RS (1) | RS60343B1 (enExample) |
| SI (1) | SI3224269T1 (enExample) |
| SM (1) | SMT202000276T1 (enExample) |
| WO (1) | WO2016082789A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2738526T3 (es) | 2011-10-14 | 2020-01-23 | Sage Therapeutics Inc | Compuestos 19-norpregnano 3,3-disustituidos, composiciones y usos de los mismos |
| IL275725B (en) | 2012-08-21 | 2022-08-01 | Sage Therapeutics Inc | Treatment methods for epilepsy and status epilepticus |
| WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| US9725481B2 (en) | 2013-04-17 | 2017-08-08 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof |
| RS60420B1 (sr) | 2013-04-17 | 2020-07-31 | Sage Therapeutics Inc | 19-nor neuroaktivni steroidi za metode lečenja |
| AU2014256229B2 (en) | 2013-04-17 | 2018-10-04 | Sage Therapeutics, Inc. | 19-nor C3,3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof |
| PL3021852T3 (pl) | 2013-07-19 | 2021-07-05 | Sage Therapeutics, Inc. | Neuroaktywne steroidy, kompozycje i ich zastosowania |
| JP6466942B2 (ja) | 2013-08-23 | 2019-02-06 | セージ セラピューティクス， インコーポレイテッド | 向神経活性ステロイド、組成物、及びその使用 |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| WO2016061527A1 (en) | 2014-10-16 | 2016-04-21 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| HUE051488T2 (hu) | 2014-10-16 | 2021-03-01 | Sage Therapeutics Inc | Készítmények és eljárások központi idegrendszeri rendellenességek kezelésére |
| US10774108B2 (en) * | 2014-11-27 | 2020-09-15 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
| PL3250210T3 (pl) | 2015-01-26 | 2021-07-26 | Sage Therapeutics, Inc. | Kompozycje i sposoby leczenia zaburzeń OUN |
| JP6875996B2 (ja) | 2015-02-20 | 2021-05-26 | セージ セラピューティクス， インコーポレイテッド | 神経刺激性ステロイド、組成物、およびその使用 |
| EP3377070A4 (en) * | 2015-11-20 | 2019-07-10 | Sage Therapeutics, Inc. | COMPOUNDS AND METHOD FOR THEIR USE |
| WO2017148902A1 (de) * | 2016-03-03 | 2017-09-08 | Bayer Pharma Aktiengesellschaft | Neue 2-substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln |
| JP7049313B2 (ja) * | 2016-07-11 | 2022-04-06 | セージ セラピューティクス， インコーポレイテッド | Ｃ１７、ｃ２０、およびｃ２１置換神経刺激性ステロイドおよびそれらの使用方法 |
| ES2992037T3 (es) | 2016-07-11 | 2024-12-05 | Sage Therapeutics Inc | Esteroides neuroactivos sustituidos en C7, C12 y C16 y sus procedimientos de utilización |
| NZ791594A (en) | 2016-08-23 | 2025-08-29 | Sage Therapeutics Inc | A crystalline 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroid |
| WO2019113494A1 (en) | 2017-12-08 | 2019-06-13 | Sage Therapeutics, Inc. | Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders |
| ES2991092T3 (es) * | 2017-12-22 | 2024-12-02 | Sage Therapeutics Inc | Compuestos 19-homo, 3-alfa-hidroxi-esteroides-20-ona para el tratamiento de trastornos del SNC |
| JP2022501348A (ja) * | 2018-09-19 | 2022-01-06 | モデルナティエックス インコーポレイテッドModernaTX, Inc. | ステロール類似体及びその使用 |
| CN109369762B (zh) * | 2018-10-31 | 2021-06-18 | 湖南玉新药业有限公司 | 17-甲酸甾族化合物的制备方法 |
| CN109503694A (zh) * | 2018-11-21 | 2019-03-22 | 苏州闻天医药科技有限公司 | 一种新型gabaa受体调节剂及其用途 |
| CR20240234A (es) | 2019-05-31 | 2024-07-09 | Sage Therapeutics Inc | ESTEROIDES NEUROACTIVOS Y COMPOSICIONES DE ESTOS (Divisional 2021-629) |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| PE20221911A1 (es) | 2020-03-25 | 2022-12-23 | Sage Therapeutics Inc | Uso de agentes para el tratamiento de condiciones respiratorias |
| US12208103B1 (en) | 2021-05-07 | 2025-01-28 | Lipocine Inc. | Compositions and methods for treating CNS disorders |
| US11337987B1 (en) | 2021-05-07 | 2022-05-24 | Lipocine Inc. | Compositions and methods for treating central nervous system disorders |
Family Cites Families (151)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2856415A (en) | 1957-11-13 | 1958-10-14 | Searle & Co | 3,19-dihydroxy-5-androstene derivatives |
| FR1380417A (fr) | 1962-05-15 | 1964-12-04 | Roussel Uclaf | Nouveaux androstanyl-pyrazoles et procédé de préparation |
| US3206459A (en) | 1962-10-19 | 1965-09-14 | Syntex Corp | 10alpha-pregnan-19-ol derivatives |
| US3169134A (en) | 1963-03-21 | 1965-02-09 | Searle & Co | 2, 3-oxygenated-17alpha-methyl-5alpha-androstan-17beta-ols |
| BE754111A (fr) | 1969-07-29 | 1971-01-29 | Upjohn Co | Nouveaux 7alpha- et 7beta-methyl-3alpha,5alpha- cycloandrostanes et composes analogues 19-nor et leur procede de preparation |
| GB1380246A (en) * | 1970-12-17 | 1975-01-08 | Glaxo Lab Ltd | 3alpha-hydroxy-androstanes and esters thereof |
| US3943124A (en) | 1970-12-17 | 1976-03-09 | Gordon Hanley Phillipps | Chemical compounds |
| GB1434919A (en) | 1972-06-15 | 1976-05-12 | Glaxo Lab Ltd | 3alpha-hydroxy androstanes |
| US3953429A (en) * | 1970-12-17 | 1976-04-27 | Glaxo Laboratories Limited | Anaesthetic steroids of the androstance and pregnane series |
| US3983111A (en) | 1972-05-05 | 1976-09-28 | Glaxo Laboratories Limited | Steroidal anaesthetics of the pregnane and 19-norpregnane series |
| GB1430942A (en) | 1972-05-05 | 1976-04-07 | Glaxo Lab Ltd | 21-substituted 3alpha-hydroxy pregnanes |
| GB1436324A (en) * | 1972-05-12 | 1976-05-19 | Glaxo Lab Ltd | Anaesthetic 3alpha-hydroxy pregnanes |
| ES432106A1 (es) | 1973-11-30 | 1976-11-01 | Schering Ag | Procedimiento para la preparacion de d-homo-20-cetopregna- nos. |
| US4071625A (en) | 1974-05-13 | 1978-01-31 | Richardson-Merrell Inc. | 19-Oxygenated-5α-androstanes for the enhancement of libido |
| DE2438020A1 (de) | 1974-08-05 | 1976-02-26 | Schering Ag | 18-methyl-19-nor-20-keto-pregnane und verfahren zu ihrer herstellung |
| IL48628A0 (en) | 1974-12-23 | 1976-02-29 | Schering Ag | D-homo-20-keto-pregnanes and process for their manufactur |
| DE2526373C2 (de) | 1975-06-11 | 1983-11-10 | Schering AG, 1000 Berlin und 4709 Bergkamen | Verfahren zur Herstellung von Δ↑9↑↑(↑↑1↑↑1↑↑)↑-5α-20-Ketosteroiden |
| GB1570394A (en) | 1976-01-06 | 1980-07-02 | Glaxo Lab Ltd | 11-acyloxy-3-hydroxy steroids |
| US4192871A (en) | 1976-01-06 | 1980-03-11 | Glaxo Laboratories Limited | Chemical compounds |
| GB1581234A (en) * | 1976-04-05 | 1980-12-10 | Glaxo Operations Ltd | 11a - amino - 3a - hydroxysteroids |
| DE2632677A1 (de) | 1976-07-16 | 1978-01-26 | Schering Ag | Verfahren zur herstellung von androstan-17-on-derivaten und deren verwendung |
| GB1581235A (en) | 1977-04-04 | 1980-12-10 | Glaxo Operations Ltd | 11a-amino-3a-hydroxy-steroids |
| US4389345A (en) | 1981-10-09 | 1983-06-21 | G.D. Searle & Co. | 3-Oxoestra-17-acetonitrile and unsaturated analogs |
| US4495102A (en) | 1982-09-03 | 1985-01-22 | G. D. Searle & Co. | Aminoalkyl steroids |
| US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| US5120723A (en) | 1987-08-25 | 1992-06-09 | University Of Southern California | Method, compositions, and compounds for modulating brain excitability |
| US5319115A (en) | 1987-08-25 | 1994-06-07 | Cocensys Inc. | Method for making 3α-hydroxy, 3β-substituted-pregnanes |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| WO1993005786A1 (en) | 1991-09-13 | 1993-04-01 | Cocensys, Inc. | Novel gabaa receptor with steroid binding sites |
| DE4232681C2 (de) | 1992-09-29 | 1994-11-24 | Sigma Tau Ind Farmaceuti | 17-Phenyl- und 17-Furyl-14beta,5alpha-androstan- und androsten- Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzung |
| AU698834B2 (en) | 1993-05-24 | 1998-11-12 | Purdue Pharma Ltd. | Methods and compositions for inducing sleep |
| EP0656365B1 (en) | 1993-12-02 | 1997-04-09 | Akzo Nobel N.V. | Substituted 2beta-morpholinoandrostane derivatives |
| CZ300694A3 (en) | 1993-12-02 | 1996-05-15 | Akzo Nobel Nv | Substituted 2beta-morpholinandrostane derivatives, process of their preparation, their use for preparing pharmaceutical preparations and pharmaceutical compositions containing thereof |
| US5939545A (en) | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
| ATE195654T1 (de) * | 1994-02-14 | 2000-09-15 | Euro Celtique Sa | Androstane und pregnane zur allosterischen modulation des gaba-rezeptors |
| JP2002500616A (ja) | 1994-07-21 | 2002-01-08 | ファルマシア・アンド・アップジョン・カンパニー | 神経学的に活性なアミノステロイド |
| DE69519945T2 (de) | 1994-11-23 | 2001-06-07 | Cocensys, Inc. | Androstan- und pregnanserien für die allosterische modulation des gaba-rezeptors |
| KR19990022323A (ko) | 1995-06-06 | 1999-03-25 | 씨. 랜 낸시 | 안드로스탄 및 프레그난 시리즈의 신경활성 스테로이드 |
| WO1998005337A1 (en) * | 1996-08-01 | 1998-02-12 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| US5994334A (en) | 1997-02-05 | 1999-11-30 | University Of Maryland | Androgen synthesis inhibitors |
| US5935545A (en) | 1997-07-11 | 1999-08-10 | E. I. Du Pont De Nemours And Company | Process for producing an aqueous solution comprising ferric chloride |
| AU756001B2 (en) * | 1998-03-11 | 2003-01-02 | Umecrine Mood Ab | Epiallopregnanolone in the treatment of CNS disorders |
| YU77701A (sh) | 1999-04-29 | 2005-07-19 | Euro-Celtique S.A. | 3-α-HIDROKSI-3Гџ-METOKSIMETIL-21-HETEROCIKLIČNO SUPSTITUISANI STEROIDI SA ANESTETIČKIM DEJSTVOM |
| US7018406B2 (en) | 1999-11-17 | 2006-03-28 | Corevalve Sa | Prosthetic valve for transluminal delivery |
| ES2243442T3 (es) | 2000-02-18 | 2005-12-01 | Taiho Pharmaceutical Company Limited | Procedimiento de preparacion de derivados esteroides. |
| US6855836B2 (en) | 2000-10-26 | 2005-02-15 | Jenapharm Gmbh & Co. Kg | 17-Methylene steroids, process for their production and pharmaceutical compositions that contain these compounds |
| JP2004518637A (ja) | 2000-11-03 | 2004-06-24 | ワシントン・ユニバーシティ | 細胞保護活性を有する修飾されたヒドロキシ置換芳香族構造体 |
| GR1003861B (el) | 2000-12-29 | 2002-04-11 | Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa. | |
| AU2004224053B2 (en) | 2003-03-24 | 2011-06-09 | Sterix Limited | Oestrogen derivatives as inhibitors of steroid sulphatase |
| EP1626980A4 (en) | 2003-05-29 | 2007-07-04 | Univ Washington | NEUROACTIVE 13,24-CYCLO-18,21-DINORCHOLANES AND STRUCTURELY RELATED PENTACYCLIC STEROIDS |
| AU2004292555A1 (en) | 2003-11-24 | 2005-06-09 | Merck & Co., Inc. | Estrogen receptor modulators |
| WO2005105822A2 (en) | 2004-04-23 | 2005-11-10 | Euro-Celtique S.A. | 3-alpha-hydroxy 21-n- heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof |
| US8604011B2 (en) | 2004-09-27 | 2013-12-10 | The Regents Of The University Of California | Therapy for treatment of chronic degenerative brain diseases and nervous system injury |
| EP1807118B8 (en) | 2004-09-29 | 2014-04-23 | Harbor Therapeutics, Inc. | Steroid analogs and characterization and treatment methods |
| EP1888080B1 (en) | 2005-06-09 | 2010-04-14 | Euro-Celtique S.A. | Pharmaceutical compositions of a neuroactive steroid and uses thereof |
| ES2607852T3 (es) * | 2006-11-21 | 2017-04-04 | Umecrine Ab | El uso de esteroides de pregnano y androstano para la fabricación de una composición farmacéutica para el tratamiento de trastornos del SNC |
| US20090203658A1 (en) | 2007-01-08 | 2009-08-13 | Duke University | Neuroactive steroid compositions and methods of use therefor |
| DE102007027636A1 (de) | 2007-06-12 | 2008-12-18 | Bayer Schering Pharma Aktiengesellschaft | 17ß-Cyano-18a-homo-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel |
| AU2008265898B2 (en) | 2007-06-15 | 2013-11-28 | Research Triangle Institute | Androstane and pregnane steroids with potent allosteric GABA receptor chloride ionophore modulating properties |
| GB0711948D0 (en) | 2007-06-20 | 2007-08-01 | Bionature E A Ltd | Neurosteriod compounds |
| CN101412742B (zh) | 2007-10-19 | 2013-07-31 | 天津金耀集团有限公司 | 一种抑制血管新生的硝酸酯药物 |
| US20090264443A1 (en) | 2008-04-18 | 2009-10-22 | David Helton | Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds |
| CN101624414B (zh) | 2008-07-07 | 2013-02-13 | 天津金耀集团有限公司 | 一种抑制血管新生的硝酸酯药物 |
| CZ2008434A3 (cs) | 2008-07-10 | 2009-12-09 | Ústav organické chemie a biochemie Akademie ved CR, v. v. i. | Pregnanové anionické slouceniny, zpusob jejich výroby a jejich použití |
| WO2010054158A2 (en) | 2008-11-07 | 2010-05-14 | Auspex Pharmaceuticals, Inc. | Steroid modulators of glucocorticoid receptor |
| WO2011079047A1 (en) | 2009-12-23 | 2011-06-30 | Drugtech Corporation | Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions |
| US20130303500A1 (en) | 2010-07-30 | 2013-11-14 | Medexis S.A. | Compounds and methods for treating neoplasia |
| WO2012083090A2 (en) | 2010-12-15 | 2012-06-21 | Harbor Biosciences, Inc. | Methods and compounds for preparing 3alpha-oxygen substituted steroids |
| CZ201181A3 (cs) | 2011-02-15 | 2012-09-12 | Ústav organické chemie a biochemie Akademie ved CR, v.v.i. | Deriváty pregnanolonu substituované v poloze 3alfa kationickou skupinou, zpusob jejich výroby, jejich použití a prostredek je obsahující |
| EP2675822A4 (en) | 2011-02-15 | 2014-07-30 | Socpra Sciences Et Génie S E C | STEROID ALKALOIDS AND THEIR USE AS ANTIMICROBIAL AGENTS AGAINST MICROORGANISMS WITH ELECTRON TRANSPORT FAILURE AND AS MICROBIAL AGENT EXHAUSTERS AGAINST PATHOGENIC BACTERIA |
| US9388210B2 (en) | 2011-02-25 | 2016-07-12 | Washington University | Neuroactive 17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
| EP2987866B1 (en) | 2011-03-23 | 2017-12-06 | Etsuro Ito | Method and kit for super-high-sensitivity measurement of protein and nucleic acid, and novel enzyme substrate |
| WO2013019711A2 (en) | 2011-07-29 | 2013-02-07 | The Regents Of The University Of California | NOVEL 17β-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS |
| CN107936076B (zh) | 2011-09-08 | 2021-10-15 | 萨奇治疗股份有限公司 | 神经活性类固醇、组合物、及其用途 |
| ES2738526T3 (es) | 2011-10-14 | 2020-01-23 | Sage Therapeutics Inc | Compuestos 19-norpregnano 3,3-disustituidos, composiciones y usos de los mismos |
| NZ773177A (en) | 2012-01-23 | 2022-09-30 | Sage Therapeutics Inc | Neuroactive steroid formulations and methods of treating cns disorders |
| WO2013188792A2 (en) | 2012-06-15 | 2013-12-19 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| NZ734451A (en) | 2012-06-19 | 2018-12-21 | Intercept Pharmaceuticals Inc | Preparation, uses and solid forms of obeticholic acid |
| WO2014028398A2 (en) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids |
| IL275725B (en) | 2012-08-21 | 2022-08-01 | Sage Therapeutics Inc | Treatment methods for epilepsy and status epilepticus |
| US9765110B2 (en) | 2012-10-08 | 2017-09-19 | Washington University | Neuroactive 19-alkoxy-17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
| WO2014071449A1 (en) * | 2012-11-09 | 2014-05-15 | Goodchild Investments Pty Ltd | Neuroactive steroids and their use to facilitate neuroprotection |
| DK2925327T3 (da) | 2012-11-30 | 2024-03-25 | Univ California | Allopregnanolon til behandling, reduktion eller lindring af symptomer på fødselsdepression |
| JP6542127B2 (ja) | 2012-12-18 | 2019-07-10 | ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ | 向神経活性１９−アルコキシ−１７−置換ステロイド、そのプロドラッグおよびそれを使用する処置方法 |
| US8939545B2 (en) | 2012-12-20 | 2015-01-27 | Eastman Kodak Company | Inkjet printing with managed airflow for condensation control |
| WO2014108808A2 (en) | 2013-01-09 | 2014-07-17 | Henry James Lorne | Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration |
| CA2831054C (en) | 2013-01-09 | 2016-08-30 | Sapna Life Sciences Corp. | Formulations, and methods for their use in treatment of neuropathology and neurodegeneration as a result of traumatic injury |
| GB201302368D0 (en) | 2013-02-11 | 2013-03-27 | Univ Bath | Compound |
| US9512170B2 (en) | 2013-03-01 | 2016-12-06 | Washington University | Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors |
| US9562026B2 (en) | 2013-03-14 | 2017-02-07 | Washington University | Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors |
| AU2014256229B2 (en) | 2013-04-17 | 2018-10-04 | Sage Therapeutics, Inc. | 19-nor C3,3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof |
| WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| US9725481B2 (en) | 2013-04-17 | 2017-08-08 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof |
| RS60420B1 (sr) * | 2013-04-17 | 2020-07-31 | Sage Therapeutics Inc | 19-nor neuroaktivni steroidi za metode lečenja |
| PL3021852T3 (pl) | 2013-07-19 | 2021-07-05 | Sage Therapeutics, Inc. | Neuroaktywne steroidy, kompozycje i ich zastosowania |
| JP6466942B2 (ja) | 2013-08-23 | 2019-02-06 | セージ セラピューティクス， インコーポレイテッド | 向神経活性ステロイド、組成物、及びその使用 |
| EP4144746A1 (en) | 2014-05-29 | 2023-03-08 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions and uses thereof |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| WO2016036724A1 (en) | 2014-09-02 | 2016-03-10 | The Texas A&M University System | Method of treating organophosphate intoxication |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| HUE051488T2 (hu) | 2014-10-16 | 2021-03-01 | Sage Therapeutics Inc | Készítmények és eljárások központi idegrendszeri rendellenességek kezelésére |
| WO2016061527A1 (en) | 2014-10-16 | 2016-04-21 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| US10774108B2 (en) | 2014-11-27 | 2020-09-15 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
| PL3250210T3 (pl) | 2015-01-26 | 2021-07-26 | Sage Therapeutics, Inc. | Kompozycje i sposoby leczenia zaburzeń OUN |
| CN105985396A (zh) | 2015-02-16 | 2016-10-05 | 苏州泽璟生物制药有限公司 | 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物 |
| JP6875996B2 (ja) | 2015-02-20 | 2021-05-26 | セージ セラピューティクス， インコーポレイテッド | 神経刺激性ステロイド、組成物、およびその使用 |
| WO2016164763A1 (en) | 2015-04-10 | 2016-10-13 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| MA45276A (fr) | 2015-06-18 | 2018-04-25 | Sage Therapeutics Inc | Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation |
| UY36741A (es) | 2015-06-21 | 2016-12-30 | Prevacus Inc | Compuesto de esteroide c-20, sus composiciones y usos para tratar la lesión cerebral traumática (tbi), que incluye las conmociones cerebrales |
| JP2018526423A (ja) | 2015-09-08 | 2018-09-13 | ビューポイント セラピューティクス， インコーポレイテッド | 眼科疾患を処置するための化合物および製剤 |
| US10780099B2 (en) | 2015-10-16 | 2020-09-22 | Marinus Pharmaceuticals, Inc. | Injectable neurosteroid formulations containing nanoparticles |
| EP3377070A4 (en) | 2015-11-20 | 2019-07-10 | Sage Therapeutics, Inc. | COMPOUNDS AND METHOD FOR THEIR USE |
| WO2017156103A1 (en) | 2016-03-08 | 2017-09-14 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| US10226550B2 (en) | 2016-03-11 | 2019-03-12 | Brigham Young University | Cationic steroidal antimicrobial compositions for the treatment of dermal tissue |
| JP7049313B2 (ja) | 2016-07-11 | 2022-04-06 | セージ セラピューティクス， インコーポレイテッド | Ｃ１７、ｃ２０、およびｃ２１置換神経刺激性ステロイドおよびそれらの使用方法 |
| ES2992037T3 (es) | 2016-07-11 | 2024-12-05 | Sage Therapeutics Inc | Esteroides neuroactivos sustituidos en C7, C12 y C16 y sus procedimientos de utilización |
| NZ791594A (en) | 2016-08-23 | 2025-08-29 | Sage Therapeutics Inc | A crystalline 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroid |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| CN108727453A (zh) | 2017-04-20 | 2018-11-02 | 华东理工大学 | 新型pd-1抑制剂及其应用 |
| WO2019018119A1 (en) | 2017-07-18 | 2019-01-24 | Pairnomix, Llc | METHODS FOR TREATING EPILEPSY AND DISORDERS ASSOCIATED WITH KCNTI |
| MX2020001732A (es) | 2017-08-31 | 2020-03-20 | Takeda Pharmaceuticals Co | Tratamiento de las afecciones del sistema nervioso central. |
| EP3678670A1 (en) | 2017-09-07 | 2020-07-15 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
| WO2019051477A1 (en) | 2017-09-11 | 2019-03-14 | Sage Therapeutics, Inc. | METHODS OF TREATING EPILEPSY OR EPILEPTIC MALE CONDITION |
| EP3681510A1 (en) | 2017-09-14 | 2020-07-22 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
| AU2018364659A1 (en) | 2017-11-10 | 2020-05-28 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treating genetic epileptic disoders |
| WO2019113494A1 (en) | 2017-12-08 | 2019-06-13 | Sage Therapeutics, Inc. | Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders |
| AR114044A1 (es) | 2017-12-22 | 2020-07-15 | Sage Therapeutics Inc | Composiciones y métodos para el tratamiento de trastornos en el sistema nervioso central |
| ES2991092T3 (es) | 2017-12-22 | 2024-12-02 | Sage Therapeutics Inc | Compuestos 19-homo, 3-alfa-hidroxi-esteroides-20-ona para el tratamiento de trastornos del SNC |
| EP3737687B1 (en) | 2018-01-12 | 2025-10-22 | Sage Therapeutics, Inc. | Aza-, oxa and thia-pregnan-20-one-3.alpha.-ol compounds for use in treating cns disorders |
| WO2019241442A1 (en) | 2018-06-12 | 2019-12-19 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof |
| US11634453B2 (en) | 2018-10-12 | 2023-04-25 | Sage Therapeutics, Inc. | Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of CNS disorders |
| EP3867261B1 (en) | 2018-10-19 | 2025-04-30 | Sage Therapeutics, Inc. | 9(11)-unsaturated neuroactive steroids and their methods of use |
| TWI874337B (zh) | 2018-12-05 | 2025-03-01 | 美商賽吉醫療公司 | 神經活性類固醇及其使用方法 |
| JP7692830B2 (ja) | 2018-12-21 | 2025-06-16 | セージ セラピューティクス， インコーポレイテッド | ３α－ヒドロキシ－１７β－アミド神経刺激性ステロイドおよびその組成物 |
| TW202523658A (zh) | 2019-05-24 | 2025-06-16 | 美商賽吉醫療公司 | 化合物、組合物及使用方法 |
| CR20240234A (es) | 2019-05-31 | 2024-07-09 | Sage Therapeutics Inc | ESTEROIDES NEUROACTIVOS Y COMPOSICIONES DE ESTOS (Divisional 2021-629) |
| KR20220038681A (ko) | 2019-06-27 | 2022-03-29 | 세이지 테라퓨틱스, 인크. | Cns 장애를 치료하기 위한 조성물 및 방법 |
| TWI896547B (zh) | 2019-06-27 | 2025-09-11 | 美商賽吉醫療公司 | 用於治療cns病症之組合物及方法 |
| CA3143545A1 (en) | 2019-06-27 | 2020-12-30 | Sage Therapeutics, Inc. | Compounds for treating cns disorders |
| CA3163556A1 (en) | 2019-12-05 | 2021-06-10 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
| TW202143976A (zh) | 2020-03-18 | 2021-12-01 | 美商賽吉醫療公司 | 神經活性類固醇及其使用方法 |
| PE20221911A1 (es) | 2020-03-25 | 2022-12-23 | Sage Therapeutics Inc | Uso de agentes para el tratamiento de condiciones respiratorias |
| CA3183248A1 (en) | 2020-06-24 | 2021-12-30 | Sage Therapeutics, Inc. | 3.alpha.-hydroxy, 17.beta.-c(o)-n-aryl substituted neuroactive steroids and compositions thereof |
| CA3187178A1 (en) | 2020-07-20 | 2022-01-27 | Sage Therapeutics, Inc. | Formulations of 19-nor c3,3- disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
| KR20230124916A (ko) | 2020-11-25 | 2023-08-28 | 세이지 테라퓨틱스, 인크. | Cns 장애를 치료하기 위한 조성물 및 방법 |
| IL304080A (en) | 2021-01-28 | 2023-08-01 | Sage Therapeutics Inc | Use of neuroactive steroids for treatment of sexual dysfunction |
| WO2022177718A1 (en) | 2021-02-18 | 2022-08-25 | Sage Therapeutics, Inc. | Use of neuroactive steroid for treatment of sexual dysfunction |
| MX2023010728A (es) | 2021-03-17 | 2024-02-12 | Sage Therapeutics Inc | Un esteroide de c21-n-pirazolilo 19-nor c3,3-disustituido para el tratamiento de trastorno depresivo mayor. |
| EP4322960A1 (en) | 2021-04-12 | 2024-02-21 | Sage Therapeutics, Inc. | Treatment of essential tremor |
| IL307980A (en) | 2021-04-29 | 2023-12-01 | Sage Therapeutics Inc | A neuroactive steroid for use in the treatment of major depressive disorder and postpartum depression in the lactating female |
| CA3218072A1 (en) | 2021-04-29 | 2022-11-03 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression |
-
2015
- 2015-11-27 US US15/531,313 patent/US10774108B2/en active Active
- 2015-11-27 SM SM20200276T patent/SMT202000276T1/it unknown
- 2015-11-27 ES ES15862506T patent/ES2793237T3/es active Active
- 2015-11-27 ME MEP-2020-105A patent/ME03749B/me unknown
- 2015-11-27 HR HRP20200840TT patent/HRP20200840T1/hr unknown
- 2015-11-27 RS RS20200610A patent/RS60343B1/sr unknown
- 2015-11-27 WO PCT/CN2015/095765 patent/WO2016082789A1/en not_active Ceased
- 2015-11-27 EP EP20159317.5A patent/EP3719029A1/en not_active Ceased
- 2015-11-27 JP JP2017528154A patent/JP6893173B2/ja active Active
- 2015-11-27 PT PT158625061T patent/PT3224269T/pt unknown
- 2015-11-27 LT LTEP15862506.1T patent/LT3224269T/lt unknown
- 2015-11-27 DK DK15862506.1T patent/DK3224269T3/da active
- 2015-11-27 SI SI201531219T patent/SI3224269T1/sl unknown
- 2015-11-27 HU HUE15862506A patent/HUE049014T2/hu unknown
- 2015-11-27 PL PL15862506T patent/PL3224269T3/pl unknown
- 2015-11-27 EP EP15862506.1A patent/EP3224269B1/en active Active
-
2020
- 2020-02-25 US US16/800,053 patent/US20210017218A1/en not_active Abandoned
- 2020-05-26 CY CY20201100480T patent/CY1123200T1/el unknown
-
2021
- 2021-05-31 JP JP2021090965A patent/JP7186259B2/ja active Active
-
2022
- 2022-10-04 US US17/959,592 patent/US11945836B2/en active Active
- 2022-11-28 JP JP2022189056A patent/JP2023022187A/ja active Pending
-
2024
- 2024-02-20 US US18/581,595 patent/US20250042934A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3719029A1 (en) | 2020-10-07 |
| JP7186259B2 (ja) | 2022-12-08 |
| US20170342102A1 (en) | 2017-11-30 |
| JP2023022187A (ja) | 2023-02-14 |
| DK3224269T3 (da) | 2020-05-25 |
| EP3224269A1 (en) | 2017-10-04 |
| LT3224269T (lt) | 2020-07-10 |
| JP2017535586A (ja) | 2017-11-30 |
| US20250042934A1 (en) | 2025-02-06 |
| US20230279043A1 (en) | 2023-09-07 |
| HRP20200840T1 (hr) | 2020-11-13 |
| JP2021130698A (ja) | 2021-09-09 |
| CY1123200T1 (el) | 2021-10-29 |
| SMT202000276T1 (it) | 2020-07-08 |
| US20210017218A1 (en) | 2021-01-21 |
| ME03749B (me) | 2021-04-20 |
| US10774108B2 (en) | 2020-09-15 |
| JP6893173B2 (ja) | 2021-06-23 |
| EP3224269B1 (en) | 2020-02-26 |
| RS60343B1 (sr) | 2020-07-31 |
| PT3224269T (pt) | 2020-06-01 |
| HUE049014T2 (hu) | 2020-09-28 |
| WO2016082789A1 (en) | 2016-06-02 |
| EP3224269A4 (en) | 2018-07-25 |
| US11945836B2 (en) | 2024-04-02 |
| PL3224269T3 (pl) | 2020-08-24 |
| SI3224269T1 (sl) | 2020-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2793237T3 (es) | Composiciones y métodos para el tratamiento de trastornos del SNC | |
| AU2022209232B2 (en) | C17, C20, and C21 substituted neuroactive steroids and their methods of use | |
| AU2022203444B2 (en) | Compositions and methods for treating CNS disorders | |
| ES2848823T3 (es) | Esteroides neuroactivos, composiciones y usos de los mismos | |
| ES2992037T3 (es) | Esteroides neuroactivos sustituidos en C7, C12 y C16 y sus procedimientos de utilización | |
| ES2857082T3 (es) | Composiciones y métodos para el tratamiento de trastornos del SNC | |
| ES2966055T3 (es) | Esteroides neuroactivos sustituidos en la posición 10 con un grupo cíclico para su uso en el tratamiento de trastornos del SNC | |
| BR112021012242A2 (pt) | Esteroides neuroativos de 3-alfa-hidróxi-17-beta-amida e composições destes | |
| RU2846188C2 (ru) | 3альфа-гидрокси-17бета-амидные нейроактивные стероиды и их композиции | |
| HK40105117A (en) | C17, c20, and c21 substituted neuroactive steroids and their methods of use | |
| BR122024007325A2 (pt) | Compostos esteroides neuroativos de 3-alfa-hidróxi-17-beta-amida, suas composições farmacêuticas e seus usos | |
| BR122022005124B1 (pt) | Compostos esteróides neuroativos c17, c20 e c21 substituídos, suas composições farmacêuticas, seus usos e kits | |
| BR112019000578B1 (pt) | Compostos esteróides neuroativos c17, c20 e c21 substituídos, suas composições farmacêuticas e seus usos | |
| HK1236539A1 (en) | Compositions and methods for treating cns disorders | |
| BR122022005119B1 (pt) | Compostos esteróides neuroativos c17, c20 e c21 substituídos, suas composições farmacêuticas, seus usos e kits | |
| HK1236539B (en) | Compositions and methods for treating cns disorders | |
| HK40000512B (en) | C17, c20, and c21 substituted neuroactive steroids and their methods of use | |
| HK40000512A (en) | C17, c20, and c21 substituted neuroactive steroids and their methods of use |